PMID- 23313108
OWN - NLM
STAT- MEDLINE
DCOM- 20130412
LR  - 20161125
IS  - 2210-7762 (Print)
VI  - 206
IP  - 1-2
DP  - 2013 Jan-Feb
TI  - Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast 
      cancer: polyploidization can lead to diagnostic pitfalls with potential impact 
      for clinical management.
PG  - 37-41
LID - S2210-7762(12)00276-1 [pii]
LID - 10.1016/j.cancergen.2012.12.001 [doi]
AB  - The status of the HER2 (ERBB2) gene in breast cancer is not static and may change 
      among the primary tumor, lymph node metastases, and distant metastases. This 
      status change can be a consequence of the natural evolution of the tumor or can 
      be induced by therapy. The HER2 gene status is, in the majority of cases, 
      established at the moment of diagnosis. After chemotherapy, monitoring HER2 
      status can be a challenge because of ploidy changes induced by drugs. The 
      cytogeneticist or the pathologist can face real difficulties in distinguishing 
      between a true HER2 amplification and HER2 copy number increase by 
      polyploidization. We performed a HER2 genetic examination by fluorescence in situ 
      hybridization (FISH) of invasive breast cancers before and after taxane 
      treatment. The majority of patients (91%) were HER2-negative both at diagnosis 
      and after treatment. Thirty of 344 patients (9%) whose tumors were initially 
      HER2-negative were found by FISH to have supernumerary HER2 gene copies (up to 15 
      copies) after neoadjuvant chemotherapy. This HER2 copy increase could not be 
      attributed to true gene amplifications and instead reflected polyploidization 
      events, which presumably affected all chromosomes. Indeed, when we used other 
      FISH probes, we found other gene copy numbers to parallel those of HER2. We 
      recommend careful checking of invasive breast carcinomas by supplementary FISH 
      probes if the copy number of the HER2 gene is >6. This procedure allows the 
      discrimination of specific HER2 gene amplifications and global increases in 
      ploidy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Valent, Alexander
AU  - Valent A
AD  - Molecular Pathology, Department of Pathology and Medical Biology, and 
      Histocytopathology, Translational Research, Institut Gustave Roussy, Villejuif, 
      France. alexander.valent@igr.fr
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
FAU - Cayre, Anne
AU  - Cayre A
FAU - Kroemer, Guido
AU  - Kroemer G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130110
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
RN  - 0 (Aneugens)
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Taxoids)
RN  - 1605-68-1 (taxane)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aneugens/administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Breast Neoplasms/*diagnosis/drug therapy/genetics/pathology
MH  - Bridged-Ring Compounds/administration & dosage/adverse effects
MH  - Carcinoma/*diagnosis/drug therapy/genetics/pathology
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Female
MH  - Gene Amplification/drug effects
MH  - Gene Dosage/*drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Genes, erbB-2/*drug effects
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Polyploidy
MH  - Prognosis
MH  - Receptor, ErbB-2/drug effects/genetics
MH  - Taxoids/administration & dosage/adverse effects
EDAT- 2013/01/15 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/01/15 06:00
PHST- 2012/06/11 00:00 [received]
PHST- 2012/10/29 00:00 [revised]
PHST- 2012/12/03 00:00 [accepted]
PHST- 2013/01/15 06:00 [entrez]
PHST- 2013/01/15 06:00 [pubmed]
PHST- 2013/04/13 06:00 [medline]
AID - S2210-7762(12)00276-1 [pii]
AID - 10.1016/j.cancergen.2012.12.001 [doi]
PST - ppublish
SO  - Cancer Genet. 2013 Jan-Feb;206(1-2):37-41. doi: 10.1016/j.cancergen.2012.12.001. 
      Epub 2013 Jan 10.